Filing Flows › 8-K events › Karyopharm Therapeutics
Karyopharm Therapeutics: bankruptcy or receivership
Form 8-K filed Nov 3, 2026 · items 1.01, 1.03, 2.03, 2.04, 7.01, 8.01
What the filing says
On November 2, 2026 (the “Petition Date”), Karyopharm Therapeutics Inc. (the “Company”) and its subsidiary, KPT Texas LLC (the “Subsidiary” and, together with the Company, the “Debtors”) filed voluntary petitions (the “Bankruptcy Petitions”) under Chapter 11 of title 11 of the United States Code (the “Bankruptcy Code”)
Read the filing on SEC EDGAR →
What usually followsAcross 23,525 8-Ks reporting Item 1.01 (material definitive agreement) in our universe, the stock's median move the next session was 0.0% (typical size ±1.4%, up 51% of the time); over the following 21 sessions, +1.0%. Item 2.03: 0.0% next session across 13,268. Item 2.04: +0.2% next session across 188. Every item ranked →
What this kind of filing means
Item 1.01 — Entry into a material definitive agreement. A material agreement is one the company considers important enough to disclose within four business days: a merger agreement, a large supply or customer contract, a credit agreement or a licence. The terms often move the company’s outlook more than a quarter’s results.
Item 1.03 — Bankruptcy or receivership. A bankruptcy or receivership filing usually leaves common shareholders last in line; what matters is the plan, the financing and whether the shares survive.
Item 2.03 — Creation of a direct financial obligation. New debt or a guarantee: the amount, the rate and the maturity set the cost of capital and the repayment wall ahead.
Item 2.04 — Triggering events that accelerate an obligation. An event that accelerates debt — a default or covenant breach — can make borrowings due at once.
Karyopharm Therapeutics at a glance
Karyopharm Therapeutics, Q2 2026: revenue $33.4M (-12% year over year), operating margin -67.4%. The chart follows the revenue to costs, profit and cash.
Karyopharm Therapeutics: every quarter, Q/Q and Y/Y, holders and guidance →
Karyopharm Therapeutics’s other material 8-Ks
- Nov 5, 2026 — Delisting notices
- Nov 2, 2026 — FDA decisions Karyopharm Therapeutics Inc. Announces Planned Merger with Ayrmid Ltd. to Strengthen Company for the
Other recent bankruptcy
- Getty Images Holdings Oct 26, 2026
- Leslie's Oct 22, 2026
Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.